Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Roche Holding (SWX:ROG) reported positive Phase II results from its ZUPREME-1 trial of petrelintide in obesity.
The study showed meaningful weight loss and strong tolerability in participants.
The data are seen as an important step for Roche’s broader obesity pipeline and potential future combination therapies.
For investors watching SWX:ROG, this update comes with the stock at around CHF341.2 and a 1 year return of 14.8%. The shares have seen a 44.4% return over 3 years and 32.2% over 5 years, which gives some context for how the market has treated Roche over different time frames.
The ZUPREME-1 readout feeds directly into Roche’s push in metabolic disease, alongside its recent partnerships and pipeline build out. As more details emerge on regulatory plans and possible combination approaches, investors may focus on how petrelintide could fit into the broader obesity treatment mix and how that might influence Roche’s role in this therapeutic area.
Stay updated on the most important news stories for Roche Holding by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Roche Holding.
SWX:ROG Earnings & Revenue Growth as at Mar 2026
We’ve flagged 1 risk for Roche Holding. See which could impact your investment.
✅ Price vs Analyst Target: At CHF341.2, Roche trades about 5% below the CHF360.7 analyst price target.
✅ Simply Wall St Valuation: Simply Wall St currently views the shares as undervalued, trading around 61% below its estimated fair value.
❌ Recent Momentum: The 30 day return is about a 5.4% decline, so the short term trend has been weaker despite the trial news.
There is only one way to know the right time to buy, sell or hold Roche Holding. Head to Simply Wall St’s company report for the latest analysis of Roche Holding’s fair value.
📊 Positive Phase II data for petrelintide adds another asset to Roche’s obesity effort, which could become more important if combination therapies gain traction in this space.
📊 Watch how management frames next steps on Phase III timing, regulatory interactions and any read across to other metabolic pipeline assets.
⚠️ The balance sheet includes a high level of debt, so investors may want to monitor how much capital is required to move obesity programs through late stage trials.
For the full picture including more risks and rewards, check out the complete Roche Holding analysis. Alternatively, you can check out the community page for Roche Holding to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com